Actively Recruiting
Evaluation of Folate Receptor Alpha Testing Concordance Using Archived Tissue in Adult Women With Ovarian Cancer
Led by AbbVie · Updated on 2026-09-14
1000
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer, is the most deadly gynecologic cancer with a 5-year survival rate of about 50%. This observational study aims to evaluate the agreement in folate receptor alpha FRa immunohistochemistry IHC testing among adult female participants with ovarian cancer. Researchers will use archived tissue samples to assess FRa expression, collecting data from about 1,000 participants. The study involves testing stored tissue biopsies using FRa IHC to measure protein overexpression. These samples are surgical or biopsy specimens collected within the last 5 years containing enough viable tumor cells. The study has no treatment or drug administration, focusing on reviewing archived samples and participants medical charts. Participants are not required to undergo any new procedures or treatments. The research team will review existing clinical data and perform laboratory testing on stored samples. The main outcome is the measurement of FRa overexpression through IHC at local and central sites. The trial duration is about one year, with no added burden or visits for participants.
CONDITIONS
Brief Title
Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
Research Team
R
Rebekah Taylor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here